Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II: P2/P3 region and discovery of cobicistat (GS-9350).

Xu L, Liu H, Hong A, Vivian R, Murray BP, Callebaut C, Choi YC, Lee MS, Chau J, Tsai LK, Stray KM, Strickley RG, Wang J, Tong L, Swaminathan S, Rhodes GR, Desai MC.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):995-9. doi: 10.1016/j.bmcl.2013.12.057. Epub 2013 Dec 21.

PMID:
24412072
2.

Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers, part I: core region.

Liu H, Xu L, Hui H, Vivian R, Callebaut C, Murray BP, Hong A, Lee MS, Tsai LK, Chau JK, Stray KM, Cannizzaro C, Choi YC, Rhodes GR, Desai MC.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):989-94. doi: 10.1016/j.bmcl.2013.12.058. Epub 2013 Dec 19.

PMID:
24411125
3.

Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.

Flentge CA, Randolph JT, Huang PP, Klein LL, Marsh KC, Harlan JE, Kempf DJ.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5444-8. doi: 10.1016/j.bmcl.2009.07.118. Epub 2009 Jul 30.

PMID:
19679477
4.

Cobicistat, a pharmacoenhancer for HIV treatments.

Temesgen Z.

Drugs Today (Barc). 2013 Apr;49(4):233-7. doi: 10.1358/dot.2013.49.4.1947288.

PMID:
23616950
5.

Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.

Shah BM, Schafer JJ, Priano J, Squires KE.

Pharmacotherapy. 2013 Oct;33(10):1107-16. doi: 10.1002/phar.1237. Epub 2013 Mar 7. Review.

PMID:
23471741
6.

Safety of pharmacoenhancers for HIV therapy.

von Hentig N, Haberl A.

Expert Rev Clin Pharmacol. 2012 Sep;5(5):557-68. doi: 10.1586/ecp.12.45. Review.

PMID:
23121278
7.

Pharmacokinetic enhancers in HIV therapeutics.

Larson KB, Wang K, Delille C, Otofokun I, Acosta EP.

Clin Pharmacokinet. 2014 Oct;53(10):865-72. doi: 10.1007/s40262-014-0167-9. Review.

PMID:
25164142
8.

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.

Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC.

ACS Med Chem Lett. 2010 May 17;1(5):209-13. doi: 10.1021/ml1000257. eCollection 2010 Aug 12.

9.

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.

Mathias AA, German P, Murray BP, Wei L, Jain A, West S, Warren D, Hui J, Kearney BP.

Clin Pharmacol Ther. 2010 Mar;87(3):322-9. doi: 10.1038/clpt.2009.228. Epub 2009 Dec 30.

PMID:
20043009
10.

Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.

Lepist EI, Phan TK, Roy A, Tong L, Maclennan K, Murray B, Ray AS.

Antimicrob Agents Chemother. 2012 Oct;56(10):5409-13. doi: 10.1128/AAC.01089-12. Epub 2012 Jul 30.

11.

Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD.

Drug Metab Dispos. 2011 Jun;39(6):1070-8. doi: 10.1124/dmd.110.037523. Epub 2011 Mar 15.

12.

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

Gallant JE, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Moyle G, Rizzardini G, Fehr J, Liu Y, Zhong L, Callebaut C, Szwarcberg J, Rhee MS, Cheng AK.

J Infect Dis. 2013 Jul;208(1):32-9. doi: 10.1093/infdis/jit122. Epub 2013 Mar 26.

13.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
14.

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy.

von Hentig N.

HIV AIDS (Auckl). 2015 Dec 22;8:1-16. doi: 10.2147/HIV.S70836. eCollection 2016. Review.

15.

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.

Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW.

Drug Metab Dispos. 2001 May;29(5):754-60.

16.

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT.

Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.

17.

Pharmacokinetic enhancers for HIV drugs.

Xu L, Desai MC.

Curr Opin Investig Drugs. 2009 Aug;10(8):775-86. Review.

PMID:
19649922
18.

Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.

Randolph JT, Huang PP, Flosi WJ, DeGoey D, Klein LL, Yeung CM, Flentge C, Sun M, Zhao C, Dekhtyar T, Mo H, Colletti L, Kati W, Marsh KC, Molla A, Kempf DJ.

Bioorg Med Chem. 2006 Jun 15;14(12):4035-46. Epub 2006 Feb 28.

PMID:
16504523
19.

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP, Mathias A.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):32-40. doi: 10.1097/QAI.0b013e3182645648.

PMID:
22732469
20.

Ritonavir-boosted protease inhibitors in HIV therapy.

Hull MW, Montaner JS.

Ann Med. 2011 Aug;43(5):375-88. doi: 10.3109/07853890.2011.572905. Epub 2011 Apr 18. Review.

PMID:
21501034

Supplemental Content

Support Center